Romiplostim Treatment in Adults with Immune Thrombocytopenia of Varying Duration and Severity

Publisher： Karger

E-ISSN： 1421-9662|134|4|215-228

ISSN： 0001-5792

Source： Acta Haematologica, Vol.134, Iss.4, 2015-0, pp. : 215-228

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Extensive cerebral venous sinus thrombosis after romiplostim treatment for immune thrombocytopenia (ITP) despite severe thrombocytopenia

By  

INTERNAL MEDICINE JOURNAL, Vol. 45, Iss. 6, 2015-06 ,pp. : 682-683

John Wiley & Sons Inc

Access to resources Recommend Favorite

Use of eltrombopag after romiplostim in primary immune thrombocytopenia

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 1, 2015-04 ,pp. : 111-116

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of self‐administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 2, 2015-02 ,pp. : 169-176

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety of the Thrombopoiesis-Stimulating Agents for the Treatment of Immune Thrombocytopenia

By  

Current Drug Safety, Vol. 5, Iss. 2, 2010-04 ,pp. : 171-181

Bentham Science Publishers

Access to resources Recommend Favorite

Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 3, 2015-03 ,pp. : 457-464

John Wiley & Sons Inc

Access to resources Recommend Favorite